Summary
Diacetyldianhydrogalactitol (DADAG), a new alkylating hexitol derivative, was given in 30-min infusions for 5 consecutive days or as a single high-dose administration. The parent drug was eliminated in a biphasic manner, with a terminal half-life of 30–40 h. Dianhydrogalactitol (DAG), the main, pharmacologically active metabolite, appeared after a lag time of about 0.2–0.6 h. Its peak concentration was reached 1–2 h after termination of the infusion. The terminal elimination of DAG followed that of the parent compound. During the 5-day schedule slight accumulation was observed, and the plasma concentrations of both compounds approached the steady state. Over a dose range of 75–1050 mg/m2 the daily mean plasma concentrations of DADAG increased by only about 3–4 times. Dose-dependent expansions of the distribution volumes of the drug (Vc, Vλ|, Vss) were observed. The behavior of DADAG and DAG in the body could be adequately described by a three-compartment open model. After equilibration the plasma levels of the parent compound and its metabolite were determined by the rate of return of DADAG from the peripheral compartment and its conversion to DAG.
Similar content being viewed by others
References
Belej MA, Troetel WM, Weiss AJ, Stambough JE, Manthei RV (1972) The absroption and metabolism of Dibromodulcitol in patients with advanced cancer. Clin Pharmacol Ther 13: 563
Chiuten DF, Rosenzweig M, Von Hoff DD, Muggia FM (1981) Clinical trials with hexitol derivatives in the US. Cancer 47:442
Eagen RT, Ames MM, Powis G, Kovach JS (1982) Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol. Cancer Treat Rep 66: 283
Eckhardt S, Hindy I (1982) Clinical investigations. In: Eckhardt S (ed) Dibromodulcitol. Medicina, Budapest, p 167
Gibaldi M, Perrier D (1975) Pharmacokinetics. Dekker, New York
Horváth IP (1982) The pharmacokinetics and metabolism of dibromodulcitol. In: Eckhardt S (ed) Dibromodulcitol. Medicina, Budapest p 131
Horváth IP, Csetényi J, Hindy I, Kerpel-Fronius S, Institóris L, Hegedüs L, Eckhardt S (1982) Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-1048001) in man: II. Pharmacokinetics of DBD. Eur J Cancer Clin Oncol 18: 1211
Institóris L (1982) Chemical consideration in the research of DBD. In: Eckhardt S (ed) Dibromodulcitol. Medicina, Budapest p 11
Institóris L, Horváth IP, Csányi E (1967) Influence of the chemical structure on biological tendency of cytostatic compounds related to dibromomannitol. Arzneimittelforsch 17: 145
Kerpel-Fronius S (1982) Hungarian anticancer drugs. Ther Hung 30: 110
Kerpel-Fronius S, Erdélyi-Tóth V, Gyergyay F, Baki M, Hindy I, Kanyár B, Eckhardt S (1983) Phase I study of diacetyldianhydrogalactitol (DADAG) with two administration schedules. Paper presented at the Second European Conference on Clinical Oncology and Cancer Nursing Amsterdam 06-36 p 67, 2–5 Nov 1983
Kimura T, Sternson LA, Higuchi T (1976) Gas chromatographic analysis for 1,2:5,6-dianhydrogalactitol, an antineoplastic agent in plasma. Clin Chem 22: 1639
Mischler NE, Earhart RH, Carr B, Tormey DC (1979) Dibromodulcitol. A review. Cancer Treat Rev 6: 191
Ötvös L, Institóris L, Somfai Zs, Szabolcs A, Elekes I (1976) Dianhydrodulcitol derivatives as pro drugs. Paper presented at the Fifth International Symposium on Medicinal Chemistry, Paris, May 1976
Rose JQ, Yurchak AM, Jusko WJ (1981) Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 9: 389–417
Somfai-Relle S, Gáti E, Bence J, Gál F (1978) New derivatives of dianhydrogalactitol (NSC-132313) with significant antitumor activity. In: Siegenthaler W, Lüthy R (eds) Current chemotherapy, vol II. American Society of Microbiology, Washington, p 1302
Tozer TN (1983) Pharmacokinetic concepts basic to cancer chemotherapy. In: Ames MM, Powis G, Kovach JS (eds) Pharmacokinetics of anticancer agents in humans. Elsevier, Amsterdam p 49
Author information
Authors and Affiliations
Additional information
Supported in part by grants from the following organizations: State Office of Technical Development; Medical Research Board; and CHINOIN Pharmaceutical and Chemical Works
Rights and permissions
About this article
Cite this article
Erdélyi-Tóth, V., Kerpel-Fronius, S., Kanyár, B. et al. Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG). Cancer Chemother. Pharmacol. 16, 257–263 (1986). https://doi.org/10.1007/BF00293988
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00293988